Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
The decision to take an HIV test has a number of psychological aspects.
The window period is the time from infection until a test can detect any change. The average window period with HIV-1 antibody tests is 22 days for subtype B. Antigen testing cuts the window period to approximately 16 days and NAT (Nucleic Acid Testing) further reduces this period to 12 days.
Performance of medical tests is often described in terms of:
- sensitivity: The percentage of the results that will be positive when HIV is present
- specificity: The percentage of the results that will be negative when HIV is not present.
All diagnostic tests have limitations, and sometimes their use may produce erroneous or questionable results.
- False positive: The test incorrectly indicates that HIV is present in a non-infected person.
- False negative: The test incorrectly indicates that HIV is absent in an infected person.
Nonspecific reactions, hypergammaglobulinemia, or the presence of antibodies directed to other infectious agents that may be antigenically similar to HIV can produce false positive results. Autoimmune diseases, such as systemic lupus erythematosus, have also rarely caused false positive results. Most false negative results are due to the window period; other factors, such as post-exposure prophylaxis, can rarely produce false negatives.
Screening donor blood and cellular products Edit
Tests selected to screen donor blood and tissue must provide a high degree of confidence that HIV is not present (that is, a high sensitivity). A combination of antibody, antigen and nucleic acid tests are used by blood banks in Western countries. The World Health Organization estimated that, as of 2000[update]Template:Dated maintenance category, inadequate blood screening had resulted in 1 million new HIV infections worldwide.
In the USA, since 1985, all blood donations are screened with an ELISA test for HIV-1 and HIV-2, as well as a nucleic acid test. These diagnostic tests are combined with careful donor selection. As of 2001[update]Template:Dated maintenance category, the risk of transfusion-acquired HIV in the U.S. was approximately one in 2.5 million for each transfusion.
Diagnosis of HIV infection Edit
Tests used for the diagnosis of HIV infection in a particular person require a high degree of both sensitivity and specificity. In the United States, this is achieved using an algorithm combining two tests for HIV antibodies. If antibodies are detected by an initial test based on the ELISA method, then a second test using the Western blot procedure determines the size of the antigens in the test kit binding to the antibodies. The combination of these two methods is highly accurate (see below).
Human rights Edit
The UNAIDS/WHO policy statement on HIV Testing states that conditions under which people undergo HIV testing must be anchored in a human rights approach that pays due respect to ethical principles. According to these principles, the conduct of HIV testing of individuals must be
- Accompanied by counseling (for those who test positive);
- Conducted with the informed consent of the person being tested.
Considerable controversy exists over the ethical obligations of health care providers to inform the sexual partners of individuals infected with HIV that they are at risk of contracting the virus. Some legal jurisdictions permit such disclosure, while others do not. More state funded testing sites are now using confidential forms of testing. This allows for monitoring of infected individuals easily, compared to anonymous testing that has a number attached to the positive test results. Controversy exists over privacy issues.
Anonymous Testing Edit
Testing that has only a number attached to the specimen that will be delivered for testing. Items that are confirmed positive will not have the HIV infected individual's name attached to the specimen. Sites that offer this service advertise this testing option.
Routine testing recommendation Edit
In the United States, one emerging standard of care is to screen all patients for HIV in all health care settings. In 2006, the Centers for Disease Control announced an initiative for voluntary, routine testing of all Americans aged 13–64 during health care encounters. An estimated 25% of infected individuals were unaware of their status; If successful the effort was expected to reduce new infections by 30% per year. The CDC recommends elimination of requirements for written consent or extensive pre-test counseling, as barriers to widespread routine testing.
Antibody tests Edit
HIV antibody tests are specifically designed for routine diagnostic testing of adults; these tests are inexpensive and extremely accurate.
Window period Edit
Antibody tests may give false negative (no antibodies were detected despite HIV being present) results during the window period, an interval of three weeks to six months between the time of HIV infection and the production of measurable antibodies to HIV seroconversion. Most people develop detectable antibodies approximately 30 days after infection, although some seroconvert later. The vast majority of people (99%) have detectable antibodies by three months after HIV infection; a six-month window is extremely rare with modern antibody testing. During the window period, an infected person can transmit HIV to others although their HIV infection may not be detectable with an antibody test. Antiretroviral therapy during the window period can delay the formation of antibodies and extend the window period beyond 12 months. This was not the case with patients that underwent treatment with post exposure prophylaxis (PEP). Those patients must take ELISA tests at various intervals after the usual 28 day course of treatment, sometimes extending outside of the conservative window period of 6 months. Antibody tests may also yield false negative results in patients with X-linked agammaglobulinemia; other diagnostic tests should be used in such patients.
Three instances of delayed HIV seroconversion occurring in health-care workers have been reported; in these instances, the health-care workers tested negative for HIV antibodies greater than 6 months postexposure but were seropositive within 12 months after the exposure. DNA sequencing confirmed the source of infection in one instance. Two of the delayed seroconversions were associated with simultaneous exposure to hepatitis C virus (HCV). In one case, co-infection was associated with a rapidly fatal HCV disease course; however, it is not known whether HCV directly influences the risk for or course of HIV infection or is a marker for other exposure-related factors.
The enzyme-linked immunosorbent assay (ELISA), or enzyme immunoassay (EIA), was the first screening test commonly employed for HIV. It has a high sensitivity.
In an ELISA test, a person's serum is diluted 400-fold and applied to a plate to which HIV antigens have been attached. If antibodies to HIV are present in the serum, they may bind to these HIV antigens. The plate is then washed to remove all other components of the serum. A specially prepared "secondary antibody" — an antibody that binds to human antibodies — is then applied to the plate, followed by another wash. This secondary antibody is chemically linked in advance to an enzyme. Thus the plate will contain enzyme in proportion to the amount of secondary antibody bound to the plate. A substrate for the enzyme is applied, and catalysis by the enzyme leads to a change in color or fluorescence. ELISA results are reported as a number; the most controversial aspect of this test is determining the "cut-off" point between a positive and negative result.
Western blot Edit
In the Western blot procedure, cells that may be HIV-infected are opened and the proteins within are placed into a slab of gel, to which an electrical current is applied. Different proteins will move with different velocities in this field, depending on their size, while their electrical charge is leveled by a surfactant called sodium lauryl sulfate. Some commercialy prepared Western blot test kits contain the HIV proteins already on a cellulose acetate strip. Once the proteins are well-separated, they are transferred to a membrane and the procedure continues similar to an ELISA: the person's diluted serum is applied to the membrane and antibodies in the serum may attach to some of the HIV proteins. Antibodies which do not attach are washed away, and enzyme-linked antibodies with the capability to attach to the person's antibodies determine to which HIV proteins the person has antibodies.
There are no universal criteria for interpreting the Western blot test: the number of viral bands which must be present may vary. If no viral bands are detected, the result is negative. If at least one viral band for each of the GAG, POL, and ENV gene-product groups are present, the result is positive. The three-gene-product approach to Western blot interpretation has not been adopted for public health or clinical practice. Tests in which less than the required number of viral bands are detected are reported as indeterminate: a person who has an indeterminate result should be retested, as later tests may be more conclusive. Almost all HIV-infected persons with indeterminate Western-Blot results will develop a positive result when tested in one month; persistently indeterminate results over a period of six months suggests the results are not due to HIV infection. In a generally healthy low-risk population, indeterminate results on Western blot occur on the order of 1 in 5,000 patients.:However for those individuals that have had high risk exposures to individuals where HIV-2 is most prevalent, Western Africa, an inconclusive Western Blot test may prove infection with HIV-2.  The Western blot test is referred to as the 'Gold Standard', meaning it trumps any positive ELISA test.
Rapid or point-of-care tests Edit
Rapid Antibody Tests are qualitative immunoassays intended for use as a point-of-care test to aid in the diagnosis of HIV infection. These tests should be used in conjunction with the clinical status, history, and risk factors of the person being tested. The specificity of Rapid Antibody Tests in low-risk populations has not been evaluated. These tests should be used in appropriate multi-test algorithms designed for statistical validation of rapid HIV test results.
If no antibodies to HIV are detected, this does not mean the person has not been infected with HIV. It may take several months after HIV infection for the antibody response to reach detectable levels, during which time rapid testing for antibodies to HIV will not be indicative of true infection status. For most people, HIV antibodies reach a detectable level after two to six weeks.
Although these tests have high specificity, false positives do occur. Any positive test result should be confirmed by a lab using the Western Blot.
OraQuick is an antibody test that provides results in 20 minutes. The blood, plasma or oral fluid is mixed in a vial with developing solution, and the results are read from a sticklike testing device. Usually detects HIV 1 and HIV 2.
Orasure is an HIV test which uses mucosal transudate from the tissues of cheeks and gums. It is an antibody test which first employs ELISA, then Western Blot.
Uni-Gold is a rapid HIV antibody test the provides results in 10-12 minutes. A drop of blood is placed on the device with developing solution. Uni-Gold is only FDA approved to test for HIV 1.
Clearview Complete HIV 1/2 and Clearview HIV 1/2 Stat-Pak are rapid tests for the detection of HIV 1 and HIV 2 antibodies in blood, serum, or plasma samples. Results are provided within 15 minutes.
There is also a urine test; it employs both the ELISA and the Western Blot method.
Home Access Express HIV-1 Test is a FDA-approved home test: the patient collects a drop of blood and mails the sample to a laboratory; results and counseling are obtained over the phone.
iDiagnostics Rapid HIV Test is, according only to their website, a non-FDA-approved home test. The company sells a blood test and a urine test produced by InTec PRODUCTS, INC. Similar to a home pregnancy test the patient collects a drop of blood/urine and drops the sample onto a cassette. Results are read visually in 15 minutes.[unreliable source?]
The accuracy of this test has not been confirmed by the FDA, and it is not authorized for sale in the United States.
The INSTI™ HIV-1/HIV-2* Rapid Antibody Test is a rapid in vitro qualitative test for the detection of antibodies to Human Immunodeficiency Virus Type 1 in human whole blood, serum or plasma. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as a screening assay capable of providing test results in less than 60 seconds. The assay is packaged as a kit containing INSTI™ Membrane Units, Sample Diluent, Color Developer and Clarifying Solution, and is available in point-of-care use packaging, or packaging suitable for laboratory use.
Interpreting antibody tests Edit
ELISA testing alone cannot be used to diagnose HIV, even if the test suggests a high probability that antibody to HIV-1 is present. In the United States, such ELISA results are not reported as "positive" unless confirmed by a Western Blot.
The ELISA antibody tests were developed to provide a high level of confidence that donated blood was NOT infected with HIV. It is therefore not possible to conclude that blood rejected for transfusion because of a positive ELISA antibody test is in fact infected with HIV. Sometimes, retesting the donor in several months will produce a negative ELISA antibody test. This is why a confirmatory Western Blot is always used before reporting a "positive" HIV test result.
Rare false positive results due to factors unrelated to HIV exposure are found more often with the ELISA test than with the Western Blot. False positives may be associated with medical conditions such as recent acute illnesses and allergies. A rash of false positive tests in the fall of 1991 was initially blamed on the influenza vaccines used during that flu season, but further investigation traced the cross-reactivity to several relatively non-specific test kits. A false positive result does not indicate a condition of significant risk to health. When the ELISA test is combined with Western Blot, the rate of false positives is extremely low, and diagnostic accuracy is very high (see below).
- HIV antibody tests are highly sensitive, meaning they react preferentially with HIV antibodies, but not all positive or inconclusive HIV ELISA tests mean the person is infected by HIV. Risk history, and clinical judgement should be included in the assessment, and a confirmation test (Western blot) should be administered. An individual with an inconclusive test should be re-tested at a later date.
Accuracy of HIV testing Edit
Modern HIV testing is highly accurate. The evidence regarding the risks and benefits of HIV screening was reviewed in July 2005 by the U.S. Preventive Services Task Force. The authors concluded that:
...the use of repeatedly reactive enzyme immunoassay followed by confirmatory Western blot or immunofluorescent assay remains the standard method for diagnosing HIV-1 infection. A large study of HIV testing in 752 U.S. laboratories reported a sensitivity of 99.7% and specificity of 98.5% for enzyme immunoassay, and studies in U.S. blood donors reported specificities of 99.8% and greater than 99.99%. With confirmatory Western blot, the chance of a false-positive identification in a low-prevalence setting is about 1 in 250 000 (95% CI, 1 in 173 000 to 1 in 379 000).
Other studies have confirmed the accuracy of current methods of HIV testing in the United States, reporting false-positive rates of 0.0004% to 0.0007% and false-negative rates of 0.003% in the general population.
Antigen tests Edit
The p24 antigen test detects the presence of the p24 protein of HIV (also known as CA), the capsid protein of the virus. Monoclonal antibodies specific to the p24 protein are mixed with the person's blood. Any p24 protein in the person's blood will stick to the monoclonal antibody and enzyme-linked antibody to the monoclonal antibodies to p24 causes a color change if p24 was present in the sample.
This test is no longer used routinely in the US or the EU  to screen blood donations since the objective was to reduce the risk of false negatives in the window period. Nucleic acid testing (NAT) is more effective for this purpose, and p24 antigen testing is no longer indicated if a NAT test is performed. The p24 antigen test is not useful for general diagnostics, as it has very low sensitivity and only works during a certain time period after infection before the body produces antibodies to the p24 protein.
Nucleic acid based tests (NAT) Edit
Nucleic-acid-based tests amplify and detect a 142-base target sequence located in a highly conserved region of the HIV gag gene . Since 2001, donated blood in the United States has been screened with nucleic-acid-based tests, shortening the window period between infection and detectability of disease to about 12 days. Since these tests are relatively expensive, the blood is screened by first pooling some 8-24 samples and testing these together; if the pool tests positive, each sample is retested individually. A different version of this test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the management of HIV-1-infected patients.
In the RT-PCR test, viral RNA is extracted from the patient's plasma and is treated with reverse transcriptase (RT) to convert the viral RNA into cDNA. The polymerase chain reaction (PCR) process is then applied, using two primers unique to the virus's genome. After PCR amplification is complete, the resulting DNA products are hybridized to specific oligonucleotides bound to the vessel wall, and are then made visible with a probe bound to an enzyme. The amount of virus in the sample can be quantified with sufficient accuracy to detect three-fold changes.
In the Quantiplex bDNA or branched DNA test, plasma is centrifugated to concentrate the virus, which is then opened to release its RNA. Special oligonucleotides are added which bind to viral RNA and to certain oligonucleotides bound to the wall of the vessel. In this way, viral RNA is fastened to the wall. Then new oligonucleotides are added which bind at several locations to this RNA; and other oligonucelotides which bind at several locations to those oligonucleotides. This is done to amplify the signal. Finally, oligonucleotides that bind to the last set of oligonucleotides and that are bound to an enzyme are added; the enzyme action causes a color reaction which allows quantification of the viral RNA in the original sample. Monitoring the effects of antiretroviral therapy by serial measurements of plasma HIV-1 RNA with this test has been validated for patients with viral loads greater than 25,000 copies per milliliter.
- Further information: Viral load testing
Other tests used in HIV treatment Edit
The CD4 T-cell count is not an HIV test, but rather a procedure where the number of CD4 T-cells in the blood is determined.
A CD4 count does not check for the presence of HIV. It is used to monitor immune system function in HIV-positive people. Declining CD4 T-cell counts are considered to be a marker of progression of HIV infection. In HIV-positive people, AIDS is officially diagnosed when the count drops below 200 cells/μL or when certain opportunistic infections occur. This use of a CD4 count as an AIDS criterion was introduced in 1992; the value of 200 was chosen because it corresponded with a greatly increased likelihood of opportunistic infection. Lower CD4 counts in people with AIDS are indicators that prophylaxis against certain types of opportunistic infections should be instituted.
Low CD4 T-cell counts are associated with a variety of conditions, including many viral infections, bacterial infections, parasitic infections, sepsis, tuberculosis, coccidioidomycosis, burns, trauma, intravenous injections of foreign proteins, malnutrition, over-exercising, pregnancy, normal daily variation, psychological stress, and social isolation.
This test is also used occasionally to estimate immune system function for people whose CD4 T cells are impaired for reasons other than HIV infection, which include several blood diseases, several genetic disorders, and the side effects of many chemotherapy drugs.
Generally speaking, the lower the number of T cells, the lower the immune system's function will be. Normal CD4 counts are between 500 and 1500 CD4+ T cells/microliter, and the counts may fluctuate in healthy people depending on recent infection status, nutrition, exercise and other factors. Women tend to have somewhat lower counts than men.
Duo/combined tests are also available which combine antigen and antibody testing, thereby making earlier detection possible.
Criticisms of HIV tests Edit
As a result of an increase in false positive rates in 2005, New York City's Department of Health and Mental Hygiene added the option of testing finger-stick whole blood after any reactive result, before using a Western Blot test to confirm the positive result. Following a further increase of false positives in NYC DOHMH STD Clinics during the end of 2007 and beginning of 2008, their clinics opted to forgo further oral screenings, and instead reinsituted testing using finger-stick whole blood.  Although the increase in false positives in NYC DOHMH, the CDC still continues to support the use of noninvasive oral fluid specimens due to their popularity in health clinics and convenience of use. Strategies implemented to determine quality control and false positive rates were implemented. It is to be understood that any reactive OraQuick test result is a preliminary positive result and will always require a confirmatory test, regardless of the mean of testing (venipuncture whole blood, fingerstick whole blood or oral mucosal transudate fluid)  Several other testing sites who did not experience a spike in false positive rates continue to use OraSure's OraQuick HIV Anti-body Testing. 
HIV tests have been criticized by AIDS denialists (people who reject the scientific consensus that HIV causes AIDS), including the "Perth Group", led by hospital technician Eleni Papadopulos-Eleopulos, who question the very existence of HIV. Their arguments rest on theoretical issues of specificity, standardization, reproducibility, and validation and are not supported by experimental data.
The accuracy of serologic testing has been verified by isolation and culture of HIV and by detection of HIV RNA by PCR, which are widely accepted "gold standards" in microbiology. While AIDS denialists focus on individual components of HIV testing, the combination of ELISA and Western Blot used for the diagnosis of HIV is remarkably accurate, with very low false-positive and -negative rates as described above. The views of AIDS denialists are based on highly selective analysis of mostly outdated scientific papers; there is broad scientific consensus that HIV is the cause of AIDS.
Fraudulent testing Edit
There have been a number of cases of fraudulent tests being sold via mail order or the Internet to the general public. In 1997, a California man was indicted on mail fraud and wire charges for selling supposed home test kits. In 2004, the US Federal Trade Commission asked Federal Express and US Customs to confiscate shipments of the Discreet home HIV test kits, produced by Gregory Stephen Wong of Vancouver, BC. In February 2005, the US FDA issued a warning against using the rapid HIV test kits and other home use kits marketed by Globus Media of Montreal Canada.
- ↑ FDA Approves First Nucleic Acid Test (NAT) Systems to Screen Plasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) [dead link] , (archived copy)
- ↑ 2.0 2.1 C B Hare, B L Pappalardo, M P Busch, B Phelps, S S Alexander, C Ramstead, J A Levy, F M Hecht (2004). "Negative HIV antibody test results among individuals treated with antiretroviral therapy (ART) during acute/early infection". The XV International AIDS Conference: Abstract no. MoPeB3107.
- ↑ Adverse reactions associated with blood transfusion. From the Puget Sound Blood Center. Accessed 5 Oct 2006.
- ↑ UNAIDS/WHO policy statement on HIV Testing (PDF), accessed 5 Oct 2006.
- ↑ JM Appel (June 2006). Must My Doctor Tell My Partner? Rethinking Confidentiality In the HIV Era. Medicine and Health Rhode Island.
- ↑ Armstrong WS, Taege AJ (April 2007). HIV screening for all: the new standard of care. Cleve Clin J Med 74 (4): 297–301.
- ↑ 7.0 7.1 CDC fact sheet
- ↑ Update on the HIV Antibody Test Window Period, from the Seattle and King County Public Health Department. Accessed 21 Feb 2007.
- ↑ Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997;336:919-22.
- ↑ HIV Seroconversion in HEALTH-CARE WORKERS
- ↑ J.L. Gerberding, San Francisco General Hospital, unpublished data, May 1997
- ↑ Bartlett, JG. Serologic tests for the diagnosis of HIV infection, in UpToDate. Accessed 5 Oct 2006.
- ↑ Scand J Infect Dis. 1992;24(4):419-21. Accessed 23 Sep 2008.
- ↑ http://www.idiagnosticsco.com/index.php/about/
- ↑ http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ComplianceActivities/Enforcement/UntitledLetters/ucm091993.htm
- ↑ http://www.biolytical.com/ourtechnology.html
- ↑ Simonsen L, Buffington J, (June 1995). Multiple false reactions in viral antibody screening assays after influenza vaccination.. Am J Epidemiol 141 (11): 1089–96.
- ↑ Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT (July 2005). Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 143 (1): 55–73.
- ↑ Kleinman S, Busch M, Hall L, Thomson R, Glynn S, Gallahan D, Ownby H, Williams A (1998). False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA 280 (12): 1080–5.
- ↑ Burke D, Brundage J, Redfield R, Damato J, Schable C, Putman P, Visintine R, Kim H (1988). Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med 319 (15): 961–4.
- ↑ 21.0 21.1 MacDonald K, Jackson J, Bowman R, Polesky H, Rhame F, Balfour H, Osterholm M (1989). Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med 110 (8): 617–21.
- ↑ 22.0 22.1 Busch M, Eble B, Khayam-Bashi H, Heilbron D, Murphy E, Kwok S, Sninsky J, Perkins H, Vyas G (1991). Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 325 (1): 1–5.
- ↑ Van de Perre P, Simonon A, Msellati P, Hitimana D, Vaira D, Bazubagira A, Van Goethem C, Stevens A, Karita E, Sondag-Thull D (1991). Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med 325 (9): 593–8.
- ↑ Update: serologic testing for HIV-1 antibody--United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep 1990; 39:380.
- ↑ Urnovitz H, Sturge J, Gottfried T (1997). Increased sensitivity of HIV-1 antibody detection. Nat Med 3 (11): 1258.
- ↑ Farzadegan H, Vlahov D, Solomon L, Muñoz A, Astemborski J, Taylor E, Burnley A, Nelson K (1993). Detection of human immunodeficiency virus type 1 infection by polymerase chain reaction in a cohort of seronegative intravenous drug users. J Infect Dis 168 (2): 327–31.
- ↑ FDA summary of branched DNA test, accessed 5 Oct 2006.
- ↑ HIV Antibody Testing - Appendix 1: Performance Characteristics of Fourth-Generation Assays
- ↑ http://www.cdc.gov/mmwr/preview/mmwrhtml/mm57e618a1.htm?s_cid=mm57e618a1_e
- ↑ 
- ↑ http://freehivtesting.hafnyc.org/node/2
- ↑ http://www.harlemunited.org/pep/testing.html
- ↑ Papadopulos-Eleopulos E, Turner V, Papadimitriou J (1993). Is a positive western blot proof of HIV infection?. Biotechnology (N Y) 11 (6): 696–707.
- ↑ AIDSTruth.org, a site focused on examining AIDS denialist claims. Accessed 5 Oct 2006.
- ↑ National Institutes of Health fact sheet on the connection between HIV and AIDS. Accessed 5 Oct 2006.
- ↑ Series of articles from Science magazine, debunking the claims of AIDS denialists. Accessed 5 Oct 2006.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|